Back to mobile site

CAMP4 Therapeutics' (CAMP) Will Enjoy Cure SYNGAP1 Partnership - Cantor Fitzgerald

December 11, 2025 7:04 AM EST Send to a Friend
Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $7.00 price target on CAMP4 Therapeutics Corp (NASDAQ: CAMP).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login